JP2014502253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502253A5 JP2014502253A5 JP2013532271A JP2013532271A JP2014502253A5 JP 2014502253 A5 JP2014502253 A5 JP 2014502253A5 JP 2013532271 A JP2013532271 A JP 2013532271A JP 2013532271 A JP2013532271 A JP 2013532271A JP 2014502253 A5 JP2014502253 A5 JP 2014502253A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- acid sequence
- sequence
- difficile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193163 Clostridioides difficile Species 0.000 claims 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 101710182223 Toxin B Proteins 0.000 claims 19
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 18
- 101710182532 Toxin a Proteins 0.000 claims 18
- 241000894006 Bacteria Species 0.000 claims 6
- 206010011409 Cross infection Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010029803 Nosocomial infection Diseases 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 239000013610 patient sample Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 108091006058 immobilized fusion proteins Proteins 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1016742.7A GB201016742D0 (en) | 2010-10-05 | 2010-10-05 | Clostridium difficile antigens |
| GB1016742.7 | 2010-10-05 | ||
| PCT/GB2011/051910 WO2012046061A2 (en) | 2010-10-05 | 2011-10-05 | Clostridium difficile antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502253A JP2014502253A (ja) | 2014-01-30 |
| JP2014502253A5 true JP2014502253A5 (enExample) | 2014-11-13 |
| JP6377907B2 JP6377907B2 (ja) | 2018-08-22 |
Family
ID=43243528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532271A Active JP6377907B2 (ja) | 2010-10-05 | 2011-10-05 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10369206B2 (enExample) |
| EP (1) | EP2625193B1 (enExample) |
| JP (1) | JP6377907B2 (enExample) |
| CN (1) | CN103237807B (enExample) |
| AU (1) | AU2011311321B2 (enExample) |
| BR (1) | BR112013008407A2 (enExample) |
| CA (1) | CA2812731C (enExample) |
| GB (1) | GB201016742D0 (enExample) |
| SG (1) | SG189058A1 (enExample) |
| WO (1) | WO2012046061A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| EP3564378B1 (en) * | 2011-05-27 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| JP2016501877A (ja) * | 2012-11-28 | 2016-01-21 | シーエヌジェー ホールディングス，インコーポレイテッド | クロストリジウム・ディフィシルに対する抗体 |
| CN103865938B (zh) * | 2012-12-16 | 2016-10-05 | 山东国际生物科技园发展有限公司 | 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用 |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| CA2910200A1 (en) * | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| GB201309421D0 (en) * | 2013-05-24 | 2013-07-10 | Imp Innovations Ltd | Polypeptides |
| CN103772509B (zh) * | 2014-01-20 | 2017-01-11 | 山东国际生物科技园发展有限公司 | 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用 |
| EP3344276B1 (en) * | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| WO2019143552A1 (en) * | 2018-01-16 | 2019-07-25 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| US11136360B2 (en) * | 2018-12-19 | 2021-10-05 | Tsinghua University | Fusion proteins comprising a Mtu ΔI-CM intein variant and methods of protein purification |
| JP7669504B2 (ja) * | 2021-02-09 | 2025-04-28 | ジョビー エアロ，インコーポレイテッド | 航空機推進ユニット |
| CN113717263B (zh) * | 2021-08-04 | 2022-06-07 | 河北医科大学第二医院 | 一种艰难梭菌特异性抗原肽 |
| CN115093470B (zh) * | 2022-06-30 | 2023-03-24 | 广州市乾相生物科技有限公司 | 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用 |
| CN120484111B (zh) * | 2025-05-14 | 2025-10-28 | 广州海绿生物技术有限公司 | 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE69535530D1 (de) * | 1994-10-24 | 2007-08-16 | Ophidian Pharm Inc | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| WO2000061762A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| AU2002232078A1 (en) | 2001-02-09 | 2002-08-19 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe | Clostridium difficile vaccine |
| DK1766093T3 (da) * | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf |
| WO2007146139A2 (en) | 2006-06-08 | 2007-12-21 | Cornell Research Foundation, Inc. | Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b |
| CA2733425A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| MX391236B (es) * | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
-
2010
- 2010-10-05 GB GBGB1016742.7A patent/GB201016742D0/en not_active Ceased
-
2011
- 2011-10-05 SG SG2013021506A patent/SG189058A1/en unknown
- 2011-10-05 WO PCT/GB2011/051910 patent/WO2012046061A2/en not_active Ceased
- 2011-10-05 EP EP11769913.2A patent/EP2625193B1/en active Active
- 2011-10-05 BR BR112013008407A patent/BR112013008407A2/pt not_active IP Right Cessation
- 2011-10-05 JP JP2013532271A patent/JP6377907B2/ja active Active
- 2011-10-05 US US13/878,150 patent/US10369206B2/en active Active
- 2011-10-05 AU AU2011311321A patent/AU2011311321B2/en active Active
- 2011-10-05 CA CA2812731A patent/CA2812731C/en active Active
- 2011-10-05 CN CN201180047913.3A patent/CN103237807B/zh active Active
-
2019
- 2019-07-15 US US16/511,503 patent/US20190328859A1/en not_active Abandoned
-
2021
- 2021-04-07 US US17/224,404 patent/US20210369830A1/en active Pending
-
2022
- 2022-08-23 US US17/821,730 patent/US12491239B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502253A5 (enExample) | ||
| Westritschnig et al. | A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers | |
| JP2012515551A5 (enExample) | ||
| JP2021038246A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| PH12013500858A1 (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments that specifically bind cd 154 and uses thereof | |
| Pathirana et al. | Characterization of proteinase–adhesin complexes of Porphyromonas gingivalis | |
| JP2016519932A5 (enExample) | ||
| de Vor et al. | Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm | |
| JP6064241B2 (ja) | 黄色ブドウ球菌由来のα毒素に対するヒトモノクローナル抗体、及び膿瘍形成の治療又は予防におけるその使用 | |
| JP2011519974A (ja) | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に特異的な抗体製剤 | |
| CN102365097A (zh) | 艰难梭菌毒素的抗体 | |
| JP2016504993A5 (enExample) | ||
| TW200626614A (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same | |
| Botelho-Nevers et al. | Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage | |
| JP2009536818A5 (enExample) | ||
| JP2007119468A (ja) | 通常のスタフィロコーカス抗原と反応する広い反応性のオプソニン抗体 | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2015529677A5 (enExample) | ||
| JP2008546648A (ja) | ブドウ球菌感染を治療および予防するためのＰａｎｔｏｎ−Ｖａｌｅｎｔｉｎｅロイコシジンの使用 | |
| JP2012523221A5 (enExample) | ||
| JP2013518563A5 (enExample) | ||
| JP2010529950A5 (enExample) | ||
| JP7643730B2 (ja) | ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物 | |
| Makam et al. | Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model | |
| Reglinski et al. | Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin |